Literature DB >> 31150553

Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden.

Vishal Bhavsar1,2, Kyriaki Kosidou3,4, Linnea Widman3,4, Nicola Orsini3, John Hodsoll1, Christina Dalman3, James H MacCabe1,2.   

Abstract

Clozapine treatment may have beneficial effects on behavioral outcomes in psychotic disorders, including violent offending. Although clozapine and other antipsychotics have been linked to lower levels of violent behavior, these have been primarily in small selected samples, and population-based estimates have been limited and imprecise. We aimed to assess the effect of clozapine treatment on the rate of violent and nonviolent offending. We carried out a within-person mirror-image study of the Swedish population with linked prescription, hospitalization, and sociodemographic registers. Outcomes were violent, nonviolent, and overall offences occurring before and after clozapine, or olanzapine, initiation. Comparison of effects of clozapine and olanzapine on key variables was modeled with interaction terms. We found periods of mirror-image observation time with clozapine treatment were associated with a much lower rate of violent offending compared to periods before treatment (rate ratio [RR]: 0.13 (95% CI: 0.05, 0.34). Reductions in nonviolent offences were smaller in magnitude (RR: 0.37, 95% CI: 0.17, 0.80). There was a statistically greater rate reduction effect on violent offences for clozapine than olanzapine (RR for interaction: 4.84, 95% CI: 1.56, 14.86, P = .002). In patients with psychotic disorders, clozapine treatment is associated with a lower rate of violent offending compared to olanzapine.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antipsychotic effectiveness; clozapine; mirror image study; olanzapine; violence; within-subject design

Mesh:

Substances:

Year:  2020        PMID: 31150553      PMCID: PMC7442333          DOI: 10.1093/schbul/sbz055

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  27 in total

Review 1.  The impact of clozapine on hospital use: a systematic review and meta-analysis.

Authors:  R Land; D Siskind; P McArdle; S Kisely; K Winckel; S A Hollingworth
Journal:  Acta Psychiatr Scand       Date:  2017-02-03       Impact factor: 6.392

2.  The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months.

Authors:  Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

3.  Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.

Authors:  Theresa Wimberley; James H MacCabe; Thomas M Laursen; Holger J Sørensen; Aske Astrup; Henriette T Horsdal; Christiane Gasse; Henrik Støvring
Journal:  Am J Psychiatry       Date:  2017-07-28       Impact factor: 18.112

Review 4.  Violence and schizophrenia: examining the evidence.

Authors:  Elizabeth Walsh; Alec Buchanan; Thomas Fahy
Journal:  Br J Psychiatry       Date:  2002-06       Impact factor: 9.319

5.  Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses.

Authors:  Birgit Ekholm; Andreas Ekholm; Rolf Adolfsson; Maria Vares; Urban Osby; Göran C Sedvall; Erik G Jönsson
Journal:  Nord J Psychiatry       Date:  2005       Impact factor: 2.202

6.  Reduction of crime in first-onset psychosis: a secondary analysis of the OPUS randomized trial.

Authors:  Hanne Stevens; Esben Agerbo; Kimberlie Dean; Preben B Mortensen; Merete Nordentoft
Journal:  J Clin Psychiatry       Date:  2013-05       Impact factor: 4.384

7.  Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.

Authors:  T Scott Stroup; Tobias Gerhard; Stephen Crystal; Cecilia Huang; Mark Olfson
Journal:  Am J Psychiatry       Date:  2015-11-06       Impact factor: 18.112

8.  External review and validation of the Swedish national inpatient register.

Authors:  Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson
Journal:  BMC Public Health       Date:  2011-06-09       Impact factor: 3.295

9.  Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.

Authors:  Heidi Taipale; Juha Mehtälä; Antti Tanskanen; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

10.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.

Authors:  Jonas F Ludvigsson; Petra Otterblad-Olausson; Birgitta U Pettersson; Anders Ekbom
Journal:  Eur J Epidemiol       Date:  2009-06-06       Impact factor: 8.082

View more
  2 in total

1.  Clozapine treatment and risk of severe COVID-19 infection.

Authors:  Anna Ohlis; Alma Sörberg Wallin; Anna Sarafis; Hugo Sjöqvist; James H MacCabe; Johan Ahlen; Christina Dalman
Journal:  Acta Psychiatr Scand       Date:  2021-10-29       Impact factor: 7.734

2.  Cognition and violent behavior in psychotic disorders: A nationwide case-control study.

Authors:  Jelle Lamsma; Wiepke Cahn; Seena Fazel
Journal:  Schizophr Res Cogn       Date:  2019-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.